Monthly Archives: June 2018

HSBC’s Major Softens Credit, Treasury Calls After Market Shakeup

HSBC Holdings Plc’s Steven Major is starting to show a little less conviction on two of his big investment calls of recent years: bullish Treasuries and bearish credit.

The shift comes as traders shaken by weeks of turbulence across asset classes regain their footing. In European credit markets, the biggest high-grade sell-off in more than two years has created a short-term buying....More>>>

ValuEngine Lowers Diageo (DEO) to Hold

Diageo (NYSE:DEO) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday.

Other analysts have also recently issued research reports about the company. Jefferies Group set a $157.00 price target on Diageo and gave the stock a “buy” rating in a research report on Thursday, January....More>>>

PayPal Stock Pays Up on Q1 Earnings Beat

Question were raised whether shares of PayPal Holdings, Inc. (PYPL) could still pay after the company’s first quarter earnings report was released Wednesday its third report since being spun out from e-commerce giant eBay, Inc. (EBAY) in July 2015.

PayPal answered that call Wednesday with interest. Its shares are up more than 2.5% in the after-hour session Wednesday,....More>>>

Auryn Resources (AUG) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Auryn Resources (NYSEAMERICAN:AUG) from a hold rating to a sell rating in a research note published on Wednesday.

According to Zacks, “Auryn Resources Inc. is a mining exploration, acquisition and development company. Its project primarily includes the Committee Bay and Gibson MacQuoid gold projects located in Nunavut, the Homestake Ridge....More>>>

4 Pressing Questions We Want Answered When Teva Pharmaceutical Reports Tomorrow Morning”

We’re in the thick of earnings season, which means some of the most prominent industry leaders are set to report their quarterly results. Tomorrow morning, Israel-based drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is set to join the crowd and release its first-quarter financial results.

Teva’s had a bumpy ride

Teva, which offers both brand-name and generic....More>>>